• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial.

作者信息

Weyer G, Erzigkeit H, Kanowski S, Ihl R, Hadler D

机构信息

Institut für Psychologie, Johann Wolfgang Goethe-Universität, Frankfurt/Main, Germany.

出版信息

Int Psychogeriatr. 1997 Jun;9(2):123-38. doi: 10.1017/s1041610297004298.

DOI:10.1017/s1041610297004298
PMID:9309486
Abstract

Psychometric characteristics of the Alzheimer's Disease Assessment Scale (ADAS) were examined on the basis of data from 440 patients with dementia of the Alzheimer type that were collected before treatment in a multicenter clinical drug trial. Coefficients of internal consistency of above .80 for the cognitive (ADAS-Cog) and the noncognitive section (ADAS-Noncog) indicated a high degree of homogeneity of item contents within the two assessment domains. Test-retest reliability was estimated to be .93, .98, and .96 for ADAS-Cog, ADAS-Noncog, and the total score (ADAS-Total), respectively. Reliably detectable individual changes, which were derived from the reliability estimates, were 7, 3, and 8 points for ADAS-Cog, ADAS-Noncog, and ADAS-Total, in that order. Factor analysis and correlations with MMSE, SKT, and NOSGER scores support the validity of the ADAS-Cog and ADAS-Noncog scores with regard to the cognitive and the noncognitive assessment domains. The ADAS summary scores, almost all of the cognitive items, and some of the noncognitive items discriminated significantly between stages of severity of dementia, as classified independently by MMSE and SKT scores.

摘要

相似文献

1
Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial.
Int Psychogeriatr. 1997 Jun;9(2):123-38. doi: 10.1017/s1041610297004298.
2
The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts.阿尔茨海默病临床试验中的 ADAS-cog:总和及其部分的心理测量评估。
J Neurol Neurosurg Psychiatry. 2010 Dec;81(12):1363-8. doi: 10.1136/jnnp.2009.204008. Epub 2010 Sep 29.
3
The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.阿尔茨海默病评估量表认知分量表(ADAS-Cog)土耳其语版本在轻度和中度阿尔茨海默病患者及正常受试者中的有效性和可靠性。
Int J Geriatr Psychiatry. 2006 Mar;21(3):259-65. doi: 10.1002/gps.1457.
4
An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.阿尔茨海默病评估量表认知分量表(ADAS-Cog)的阿拉伯文版本:信度、效度和常模数据。
J Alzheimers Dis. 2017;60(1):11-21. doi: 10.3233/JAD-170222.
5
Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.ADAS-Cog 和 NTB 量表用于测量药物反应的心理计量学评估。
Acta Neurol Scand. 2014 Feb;129(2):114-22. doi: 10.1111/ane.12153. Epub 2013 Jun 13.
6
[Adaptation and normalization of the Alzheimer's disease Assessment Scale for Spain (NORMACODEM) (II)].
Neurologia. 1997 Feb;12(2):69-77.
7
The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.阿尔茨海默病评估量表:多中心阿尔茨海默病试验中基线认知表现的模式与预测因素
Neurology. 1997 Jun;48(6):1511-7. doi: 10.1212/wnl.48.6.1511.
8
Reliability and concurrent validity of Alzheimer's disease assessment scale - Cognitive subscale, Chinese version (ADAS-Cog-C) among Chinese community-dwelling older people population.阿尔茨海默病评估量表 - 认知分量表中文版(ADAS-Cog-C)在中国社区居住老年人人群中的信度和同时效度。
Clin Neuropsychol. 2020 Dec;34(sup1):43-53. doi: 10.1080/13854046.2020.1750704. Epub 2020 Apr 11.
9
The reliability and validity of the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) among the elderly Chinese in Hong Kong.阿尔茨海默病评估量表认知分量表(ADAS-Cog)在香港老年中国人中的信度和效度。
Ann Acad Med Singap. 2000 Jul;29(4):474-85.
10
The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease.阿尔茨海默病评估量表:轻至中度阿尔茨海默病多中心临床试验中的心理测量特性评估及认知衰退模式
Alzheimer Dis Assoc Disord. 2001 Oct-Dec;15(4):174-83. doi: 10.1097/00002093-200110000-00003.

引用本文的文献

1
Analysis of practical judgment in older adults with epilepsy: An exploratory, multicenter cohort study.老年癫痫患者的实践判断力分析:一项探索性多中心队列研究。
Epilepsia. 2025 Feb;66(2):e21-e28. doi: 10.1111/epi.18228. Epub 2024 Dec 17.
2
Virtual individual cognitive stimulation therapy (V-iCST): Mixed methods feasibility randomised controlled trial.虚拟个体认知刺激疗法(V-iCST):混合方法可行性随机对照试验。
Int J Clin Health Psychol. 2024 Oct-Dec;24(4):100523. doi: 10.1016/j.ijchp.2024.100523. Epub 2024 Nov 22.
3
Efficacy of Acetylcholinesterase Inhibitors in the Logopenic Variant of Primary Progressive Aphasia.
乙酰胆碱酯酶抑制剂在原发性进行性失语症的语法缺失型变异中的疗效。
Dement Geriatr Cogn Disord. 2025;54(1):40-51. doi: 10.1159/000540932. Epub 2024 Sep 10.
4
Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns.基于脑萎缩模式预测主观认知衰退向轻度认知障碍或痴呆的进展。
Alzheimers Res Ther. 2024 Jul 5;16(1):153. doi: 10.1186/s13195-024-01517-5.
5
Discriminant Potential of the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in Greek Older Adults with Subjective Cognitive Decline and Mild Cognitive Impairment.阿尔茨海默病评估量表认知子量表(ADAS-Cog)对希腊主观认知衰退和轻度认知障碍老年人的鉴别潜力。
J Alzheimers Dis Rep. 2024 Mar 19;8(1):543-554. doi: 10.3233/ADR-230151. eCollection 2024.
6
A proof of concept phase II study with the PDE-4 inhibitor roflumilast in patients with mild cognitive impairment or mild Alzheimer's disease dementia (ROMEMA): study protocol of a double-blind, randomized, placebo-controlled, between-subjects trial.一项在轻度认知障碍或轻度阿尔茨海默病痴呆患者中使用 PDE-4 抑制剂罗氟司特的概念验证 II 期研究(ROMEMA):一项双盲、随机、安慰剂对照、组间试验的研究方案。
Trials. 2024 Mar 4;25(1):162. doi: 10.1186/s13063-024-08001-3.
7
Shortening the Alzheimer's disease assessment scale cognitive subscale.缩短阿尔茨海默病评估量表认知分量表。
Eur Psychiatry. 2024 Feb 23;67(1):e19. doi: 10.1192/j.eurpsy.2024.14.
8
Neighborhood greenspace exposure as a protective factor in dementia risk among U.S. adults 75 years or older: a cohort study.美国 75 岁及以上成年人中,社区绿地暴露作为痴呆风险的保护因素:一项队列研究。
Environ Health. 2022 Jan 15;21(1):14. doi: 10.1186/s12940-022-00830-6.
9
Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease.胆碱能激发试验的急性反应可预测阿尔茨海默病患者对加兰他敏治疗的长期反应。
Br J Clin Pharmacol. 2022 Jun;88(6):2814-2829. doi: 10.1111/bcp.15206. Epub 2022 Jan 26.
10
Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial.苯磷硫胺与阿尔茨海默病认知衰退:一项随机安慰剂对照 IIa 期临床试验结果。
J Alzheimers Dis. 2020;78(3):989-1010. doi: 10.3233/JAD-200896.